Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 5/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166081 | 1.00 | SERPINE1 (0.68) | SERPINE1HRH3ALOX5PTGS1PTGS2 | |
| SCHEMBL8639912 | 1.00 | SERPINE1 (0.68) | SERPINE1HRH3ALOX5PTGS1PTGS2 | |
| SCHEMBL8639908 | 1.00 | SERPINE1 (0.68) | SERPINE1HRH3ALOX5PTGS1PTGS2 | |
| SCHEMBL8641837 | 0.89 | SERPINE1 (0.56) | SERPINE1HRH3EP300MAPT | |
| SCHEMBL8641841 | 0.89 | SERPINE1 (0.56) | SERPINE1HRH3EP300MAPT | |
| SCHEMBL9186316 | 0.89 | SERPINE1 (0.52) | SERPINE1ALOX5PIM1CSNK2A2CSNK2B | |
| SCHEMBL9186308 | 0.89 | SERPINE1 (0.52) | SERPINE1ALOX5PIM1CSNK2A2CSNK2B | |
| SCHEMBL8412083 | 0.85 | SERPINE1 (0.49) | SERPINE1PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8412080 | 0.85 | SERPINE1 (0.49) | SERPINE1PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9183923 | 0.85 | SERPINE1 (0.49) | SERPINE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994004513-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | claimed |
| EP-3823631-B1 | METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | ASTRAZENECA AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4674485-A2 | DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE | Astrazeneca AB (SE) | 2026-01-07 | — | — | EP | disclosed |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| EP-4188389-B1 | DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE | ASTRAZENECA AB (SE) | 2025-09-17 | — | — | EP | disclosed |
| US-12409186-B2 | Methods of treating chronic kidney disease with dapagliflozin | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250161339-A1 | METHODS OF TREATING CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | ASTRAZENECA AB (SE) | 2025-05-22 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-5902812-A | Pharmaceutical piperazine compounds | XENOVA LIMITED (GB) | 1999-05-11 | — | — | US | disclosed |
| US-5861400-A | TREATING RESISTANCE TO AN ANTHRACYLCINE ANTIBIOTIC WITH ADIKETOPIPERAZINE COMPOUND | XENOVA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| US-5700804-A | INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITORS | XENOVA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0745069-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0672036-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995021831-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021830-A1 | PHARMACEUTICAL PIPERAZIN COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021829-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1994004513-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004512-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161339-A1 | METHODS OF TREATING CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A2 | SERPINE1 1718/4885HRH3 4644/4885ALOX5 2902/4885 |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | SERPINE1 53/4885HRH3 271/4885ALOX5 715/4885 |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | SERPINE1 4/4885HRH3 627/4885ALOX5 808/4885 |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | SLC5A2, SLC5A1, FABP3 | SERPINE1 750/4885HRH3 4644/4885ALOX5 1996/4885 |
| US-12409186-B2 | Methods of treating chronic kidney disease with dapagliflozin | SLC5A2, SLC5A1, SLC2A2 | SERPINE1 1718/4885HRH3 4644/4885ALOX5 2902/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | SERPINE1 13/4885HRH3 1022/4885ALOX5 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.